EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
ZY Dong, JT Zhang, SY Liu, J Su, C Zhang, Z Xie… - …, 2017 - Taylor & Francis
Patients with EGFR mutations showed unfavorable response to programmed cell death-1
(PD-1) blockade immunotherapy in non-small cell lung cancer (NSCLC). Yet the underlying …
(PD-1) blockade immunotherapy in non-small cell lung cancer (NSCLC). Yet the underlying …
[HTML][HTML] Strong programmed death ligand 1 expression predicts poor response and de novo resistance to EGFR tyrosine kinase inhibitors among NSCLC patients with …
S Su, ZY Dong, Z Xie, LX Yan, YF Li, J Su… - Journal of Thoracic …, 2018 - Elsevier
Introduction This study evaluated whether tumor expression of programmed death ligand 1
(PD-L1) could predict the response of EGFR-mutated NSCLC to EGFR tyrosine kinase …
(PD-L1) could predict the response of EGFR-mutated NSCLC to EGFR tyrosine kinase …
PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy
K Chen, G Cheng, F Zhang, G Zhu, Y Xu, X Yu… - Lung Cancer, 2020 - Elsevier
Objectives The efficacy of immunotherapy in epidermal growth factor receptor (EGFR)-
activating non-small cell lung cancer (NSCLC) is limited. However, a series of patients with …
activating non-small cell lung cancer (NSCLC) is limited. However, a series of patients with …
[HTML][HTML] Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC …
Introduction Epidermal growth factor receptor (EGFR) mutation status was reported to be
associated with programmed death-ligand 1 (PD-L1) expression. However, the molecular …
associated with programmed death-ligand 1 (PD-L1) expression. However, the molecular …
[HTML][HTML] EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
Background Although EGFR mutant tumors exhibit low response rates to immune
checkpoint blockade overall, some EGFR mutant tumors do respond to these therapies; …
checkpoint blockade overall, some EGFR mutant tumors do respond to these therapies; …
Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
K Masuda, H Horinouchi, M Tanaka… - Journal of Cancer …, 2021 - Springer
Introduction Several studies have demonstrated that non-small cell lung cancer patients
(NSCLCs) harboring epidermal growth factor receptor (EGFR) mutations have poor clinical …
(NSCLCs) harboring epidermal growth factor receptor (EGFR) mutations have poor clinical …
Immunotherapy in treating EGFR-mutant lung cancer: current challenges and new strategies
KKW To, W Fong, WCS Cho - Frontiers in Oncology, 2021 - frontiersin.org
Lung cancer is the leading cause of cancer-related deaths worldwide. Immune checkpoint
inhibitors, including monoclonal antibodies against programmed death-1 (PD-1) and …
inhibitors, including monoclonal antibodies against programmed death-1 (PD-1) and …
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer
K Isomoto, K Haratani, H Hayashi, S Shimizu… - Clinical Cancer …, 2020 - AACR
Purpose: The impact of EGFR tyrosine kinase inhibitors (TKI) on the tumor immune
microenvironment (TME) in non–small cell lung cancer (NSCLC) is unclear. Experimental …
microenvironment (TME) in non–small cell lung cancer (NSCLC) is unclear. Experimental …
Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions
K Chen, G Pan, G Cheng, F Zhang, Y Xu… - Thoracic …, 2021 - Wiley Online Library
Background Insertions in exon 20 (Ex20ins) of epidermal growth factor receptor (EGFR) and
human epidermal growth factor receptor 2 (HER2) are relatively insensitive to first‐and …
human epidermal growth factor receptor 2 (HER2) are relatively insensitive to first‐and …
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
S Peng, R Wang, X Zhang, Y Ma, L Zhong, K Li… - Molecular cancer, 2019 - Springer
Background The ATLANTIC trial reported that higher PD-L1 expression in tumors was
involved in a higher objective response in patients with EGFR+/ALK+ non-small cell lung …
involved in a higher objective response in patients with EGFR+/ALK+ non-small cell lung …
相关搜索
- nsclc patients egfr mutation
- pd l1 egfr mutation
- weak immunogenicity egfr mutation
- weak immunogenicity uninflamed phenotype
- weak immunogenicity impaired response
- uninflamed phenotype egfr mutation
- uninflamed phenotype impaired response
- pd l1 lung cancer
- impaired response egfr mutation
- egfr tki lung cancer
- death ligand egfr mutation
- pd l1 cells infiltration
- immune escape egfr mutation
- immune escape lung cancer
- poor response egfr mutation
- pd l1 egfr activation